AbbVie Bails On Harpoon’s Multiple Myeloma Drug Amid Highly Competitive Environment

 
• By Alaric DeArment

Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.

AbbVie decided not to exercise its option for Harpoon's multiple myeloma drug candidate • Source: Shutterstock

More from Immuno-oncology

More from Anticancer